Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

220

220

Fierce Pharma

NOVEMBER 12, 2024

The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. . | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5

Manufacturing 176

Manufacturing 176

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 228

Sales 228

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 183

Healthcare Healthcare 183

Fierce Pharma

NOVEMBER 4, 2024

The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

Manufacturing 184

Manufacturing Sales 184

World of DTC Marketing

MAY 9, 2022

Online ad fraud is costing pharma millions. Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. It’s no wonder that DTC marketers continue to rely on TV ads, but with more money being used for digital, one has to wonder if pharma people understand what’s going on?

Pharma 208

Pharma Media Marketing Sales 208

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

Manufacturing 230

Manufacturing Sales Medical 230

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

227

227

Fierce Pharma

JUNE 10, 2024

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

Prescription 184

Prescription Marketing 184

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Distribution 273

Distribution 273

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 287

Biopharma Government 287

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

Manufacturing 250

Manufacturing 250

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 204

Sales 204

European Pharmaceutical Review

SEPTEMBER 15, 2023

For its 20 th anniversary, more than 180 entries across 12 categories have been narrowed down to determine the finalists the upcoming CPHI Pharma Awards. To recognise the influx of innovation across the pharmaceutical industry, three new categories are included in this year’s awards.

Pharma 119

Pharma Manufacturing Biopharma Pharmaceutical 119

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 239

Sales 239

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 76

Biopharma Sales Manufacturing Pharma 76

MedCity News

OCTOBER 3, 2024

The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE.

Biopharma 108

Biopharma Pharma 108

Pharmaceutical Technology

JULY 26, 2022

NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). The deal will make NewAmsterdam Pharma a publicly listed company focusing on oral treatments for cardiometabolic diseases.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

World of DTC Marketing

FEBRUARY 22, 2021

billion by 2026. The post Jazz Pharma uses flying pig for huge grey area DTC appeared first on World of DTC Marketing.com. One of the most common complaints people have is “lack of energy” Consumers have turned to energy drinks which was valued at $53.01 This DTC is an embaressment.

Pharma 181

Pharma Doctors Side effects Prescription 181

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 197

Medical 197

MedCity News

AUGUST 15, 2024

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

Competition 122

Competition Biopharma Pharma 122

pharmaphorum

JANUARY 10, 2023

Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Pharmaceutical Technology

MAY 11, 2023

The global pharma industry experienced a 9% drop in social media posts on internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for U.S. Of the 50 leading companies in the pharma industry, U.S. Centers for Disease Control and Prevention had the most mentions of internet of things in Q1 2023.

Media 52

Media Pharma Competition Marketing 52

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 110

Biopharma Pharma 110

European Pharmaceutical Review

APRIL 15, 2024

MaaT Pharma stated that this represents “the highest overall survival” in patients with aGvHD when compared to reported evidence in the literature (Abedin et al., Advancing microbiome innovation As third line treatment, MaaT013 facilitated a 63 percent gastrointestinal overall response rate (GI-ORR) at D28 and 53 percent at D56.

Pharma 98

Pharma Patients Management Leads 98

pharmaphorum

SEPTEMBER 30, 2022

7,326,708) was challenged by Mylan Pharma, now Viatris, before the US Patent and Trademark Office (USPTO), which ruled in Merck’s favour last year. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. The US patent (No.

Marketing 59

Marketing Sales Competition FDA 59

European Pharmaceutical Review

MARCH 13, 2023

Full operations is provisionally planned for late 2026. Articles: Interchangeability of biosimilars in the EU – the industry impact… UPC opt-out – a strategic balancing act for pharma… The post Sandoz to build biologics plant in Slovenia appeared first on European Pharmaceutical Review.

Networking 97

Networking Competition Pharma Pharmaceutical 97

European Pharmaceutical Review

MAY 25, 2023

Tara Dougal, Content Director of Pharma at Informa explained that each category in 2024 Exhibitor Awards “requires an implicit sustainability focus, we hope to encourage pharma companies and product developers to consider sustainability and environmental impact at each stage of the development process”.

Pharma 95

Pharma Distribution Pharmaceutical Patients 95

Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.

Manufacturing 52

Manufacturing Medicine Sales Pharma 52

European Pharmaceutical Review

SEPTEMBER 14, 2023

Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).

Competition 97

Competition Pharma Pharmaceutical 97

European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6

Marketing 111

Marketing Government Healthcare Healthcare 111

pharmaphorum

OCTOBER 14, 2022

A consortium of industry and academic groups – led by Johnson & Johnson’s pharma division Janssen – has been set up to tackle the environmental impact of digital health products, specifically aimed at minimising waste that could end up in landfill. The project started on 1 October and is scheduled to complete in September 2026.

Leads 122

Leads Electronics Ethics Healthcare 122

European Pharmaceutical Review

MAY 11, 2023

Delivering end-to-end expertise and solutions from research discovery to development, and diagnosis to cure, Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech , diagnostic labs, academia and government agencies. Register here.

Government 96

Government Prospecting Media Marketing 96

pharmaphorum

JUNE 27, 2022

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30

Biopharma 97

Biopharma Sales Prescription FDA 97

World of DTC Marketing

OCTOBER 27, 2020

Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. By 2026, national health expenditures will reach $5.7 It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism. It’s a good read but ignores a simple fact.

Healthcare 230

Healthcare Healthcare Insurance Retail 230

pharmaphorum

JANUARY 18, 2023

NewAmsterdam Pharma’s bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib. Amgen licensed the rights to NewAmsterdam in 2020.

Pharma 59

Pharma Prospecting Patients Safety 59